StudyFinder

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

RECRUITING

The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.

I'm interested

ALL
6 years to 17 years old
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Youth ages 6-17 years with ADHD as a primary diagnosis

Exclusion Criteria:

  • Participants that do not have ADHD as a primary diagnosis
  • Participants that do not want, require, or are not healthy enough for a single dose trial of MPH for ADHD per the clinical judgment of the treating and study clinicians
  • Participants that are smokers or, are pregnant

DRUG: Methylphenidate

ADHD, Attention Deficit Hyperactivity Disorder

PK Study, PD Study, Pharmacokinetics, Pharmacodynamics, Methylphenidate, MPH

Simon Abimosleh - simon.abimosleh@cchmc.org
PHASE4
NCT03781752
See this study on ClinicalTrials.gov

Back